Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion.

Evoy KE, Abel SR.

Ann Pharmacother. 2013 Jun;47(6):819-27. doi: 10.1345/aph.1R705. Epub 2013 May 14. Review.

PMID:
23673531
2.

Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion.

Figueroa MS, Contreras I.

Drugs. 2012 Nov 12;72(16):2063-71. doi: 10.2165/11640820-000000000-00000.

PMID:
23061805
3.

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.

Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group.

Ophthalmology. 2014 Jan;121(1):202-8. doi: 10.1016/j.ophtha.2013.08.012. Epub 2013 Sep 29.

PMID:
24084497
4.

Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.

Braithwaite T, Nanji AA, Lindsley K, Greenberg PB.

Cochrane Database Syst Rev. 2014 May 1;(5):CD007325. doi: 10.1002/14651858.CD007325.pub3. Review.

5.

Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion.

Yang LP, McKeage K.

Drugs Aging. 2014 May;31(5):395-404. doi: 10.1007/s40266-014-0176-2. Review.

PMID:
24740170
6.

Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.

Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA.

Am J Ophthalmol. 2013 Mar;155(3):429-437.e7. doi: 10.1016/j.ajo.2012.09.026. Epub 2012 Dec 4.

PMID:
23218699
7.

Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.

Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA.

Ophthalmology. 2012 May;119(5):1024-32. doi: 10.1016/j.ophtha.2012.01.042. Epub 2012 Mar 21. Erratum in: Ophthalmology. 2012 Nov;119(11):2204.

PMID:
22440275
8.

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Haller JA.

Ophthalmology. 2015 Mar;122(3):538-44. doi: 10.1016/j.ophtha.2014.08.031. Epub 2014 Oct 12.

PMID:
25315663
9.

Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.

Evoy KE, Abel SR.

Ann Pharmacother. 2013 Jun;47(6):811-8. doi: 10.1345/aph.1S013. Epub 2013 May 8. Review.

PMID:
23656749
10.

Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA.

Lotery AJ, Regnier S.

Eye (Lond). 2015 Mar;29(3):380-7. doi: 10.1038/eye.2014.308. Epub 2015 Jan 9.

11.

Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group.

Am J Ophthalmol. 2014 Nov;158(5):1032-8. doi: 10.1016/j.ajo.2014.07.027. Epub 2014 Jul 25.

PMID:
25068637
12.

Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA.

Ophthalmology. 2014 Jul;121(7):1414-1420.e1. doi: 10.1016/j.ophtha.2014.01.027. Epub 2014 Mar 27. Erratum in: Ophthalmology. 2014 Nov;121(11):2293.

PMID:
24679444
13.

Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.

Zhou S, Gao J, Xu X.

Clin Experiment Ophthalmol. 2014 Sep-Oct;42(7):637-49. doi: 10.1111/ceo.12286. Epub 2014 Jan 27.

PMID:
24330277
14.

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA.

Ophthalmology. 2016 Feb;123(2):330-6. doi: 10.1016/j.ophtha.2015.09.035. Epub 2015 Oct 30.

PMID:
26522708
15.
16.

Aflibercept in wet AMD: specific role and optimal use.

Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C.

Drug Des Devel Ther. 2013 Aug 5;7:711-22. doi: 10.2147/DDDT.S40215. eCollection 2013. Review.

17.

The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.

Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A.

Klin Monbl Augenheilkd. 2015 Apr;232(4):552-5. doi: 10.1055/s-0035-1545783. Epub 2015 Apr 22.

PMID:
25902119
18.

Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.

Mayer WJ, Remy M, Wolf A, Kook D, Kampik A, Ulbig M, Reznicek L, Haritoglou C.

Ophthalmologica. 2012;228(2):110-6. doi: 10.1159/000338732. Epub 2012 Jun 23.

PMID:
22739239
19.

Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.

Yeh S, Kim SJ, Ho AC, Schoenberger SD, Bakri SJ, Ehlers JP, Thorne JE.

Ophthalmology. 2015 Apr;122(4):769-78. doi: 10.1016/j.ophtha.2014.10.013. Epub 2015 Jan 8. Review.

PMID:
25576994
20.

[Preliminary results of treatment with aflibercept].

Blăjan C, Nicula D, Rusu I.

Oftalmologia. 2014;58(4):51-8. Romanian.

PMID:
26117932
Items per page

Supplemental Content

Write to the Help Desk